By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sigma Life Science today announced a licensing deal with King's College London for the development and commercialization of technology to identify and validate miRNA targets in research and clinical diagnostics.

The technology was developed at the division of cancer studies at King's College. No further details about the technology or terms of the deal were disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.